ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

PubWeight™: 3.88‹?› | Rank: Top 1%

🔗 View Article (PMID 12637323)

Published in Blood on March 13, 2003

Authors

Sara K Vesely1, James N George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A El-Harake, Gary E Raskob

Author Affiliations

1: Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA.

Articles citing this

Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood (2008) 2.43

STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87

Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol (2008) 1.69

Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis. Blood (2008) 1.48

Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47

Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44

Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol (2010) 1.41

Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. PLoS One (2015) 1.39

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One (2010) 1.33

N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest (2011) 1.32

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27

Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 1.27

Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) (2010) 1.26

The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood (2015) 1.22

Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med (2006) 1.20

Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost (2006) 1.15

Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13

Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol (2011) 1.10

Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06

Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005. Epidemiol Infect (2007) 1.04

Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am (2007) 1.03

The thrombotic microangiopathies. Pediatr Nephrol (2007) 1.01

Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost (2005) 1.00

Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97

Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92

Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion (2011) 0.90

A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura. Hematol Rep (2011) 0.89

Thrombotic thrombocytopenic purpura mimicking acute ischemic stroke. Emerg Med J (2006) 0.89

Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl (2009) 0.88

Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. Blood Transfus (2008) 0.86

Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg (2010) 0.86

The kidney in thrombotic thrombocytopenic purpura. Minerva Med (2007) 0.85

Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States. Biol Blood Marrow Transplant (2010) 0.84

ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clin Med Res (2012) 0.84

The kidney in pregnancy: A journey of three decades. Indian J Nephrol (2012) 0.84

Therapeutic dilemma in the management of a patient with the clinical picture of TTP and severe B12 deficiency. BMC Hematol (2015) 0.83

Thrombotic thrombocytopenic purpura associated with mixed connective tissue disease: a case report. Case Rep Med (2011) 0.83

Pulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literature. Medicine (Baltimore) (2014) 0.83

A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion (2011) 0.82

The interaction between factor H and Von Willebrand factor. PLoS One (2013) 0.82

Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant (2008) 0.81

Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol (2015) 0.81

Attending rounds: microangiopathic hemolytic anemia with renal insufficiency. Clin J Am Soc Nephrol (2011) 0.81

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol (2008) 0.81

Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. Clin Rheumatol (2013) 0.81

Acute pancreatitis induced thrombotic thrombocytopenic purpura. Indian J Crit Care Med (2014) 0.81

ADAMTS13 gene mutations in children with hemolytic uremic syndrome. Yonsei Med J (2011) 0.81

Postoperative thrombotic thrombocytopenic purpura after aortofemoral bypass. J Community Hosp Intern Med Perspect (2013) 0.80

Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol (2008) 0.80

End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrol (2012) 0.80

Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome. Blood Transfus (2010) 0.79

Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol (2013) 0.79

Renal function in normal and disordered pregnancy. Curr Opin Nephrol Hypertens (2014) 0.79

Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2011) 0.79

Ciprofloxacin-Induced Thrombotic Thrombocytopenic Purpura: A Case of Successful Treatment and Review of the Literature. Case Rep Crit Care (2015) 0.79

Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol (2015) 0.78

Predictors of survival in thrombotic thrombocytopenic purpura. Haematologica (2013) 0.78

Thrombotic thrombocytopenic purpura: survival by "giving a dam". Trans Am Clin Climatol Assoc (2004) 0.78

The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost (2016) 0.78

Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 0.78

Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (Baltimore) (2015) 0.78

Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury. Crit Care Clin (2015) 0.78

Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher (2009) 0.77

Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol (2013) 0.76

ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clin J Am Soc Nephrol (2015) 0.76

Cerebral vasospasm and intracerebral haemorrhage in a case of pregnancy-related thrombotic thrombocytopoenic purpura/haemolytic uraemic syndrome. Interv Neuroradiol (2005) 0.75

Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One (2012) 0.75

Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura. Medicine (Baltimore) (2016) 0.75

Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy: first report from iran. Nephrourol Mon (2014) 0.75

Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75

Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia. Pak J Med Sci (2017) 0.75

Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients. Medicine (Baltimore) (2017) 0.75

Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). J Biol Chem (2012) 0.75

Why Do We Need ADAMTS13? Nihon Kessen Shiketsu Gakkai shi (2005) 0.75

Coagulopathy and functional hyposplenism during an episode of thrombotic thrombocytopenic purpura in a HgbS/β (+)-thalassemia patient. Clin Case Rep (2015) 0.75

Response to "Predictors of survival in thrombotic thrombocytopenic purpura" Haematologica 2013;98(5):e58. Haematologica (2013) 0.75

Differing tales of two patients after receiving a kidney transplant from a donor with disseminated intravascular coagulation. Case Rep Transplant (2014) 0.75

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood (2016) 0.75

A diagnosis of haemolytic-uraemic syndrome blurred by alcohol abuse. BMJ Case Rep (2014) 0.75

ADAMTS13 and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood (2003) 0.75

A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study. PLoS One (2014) 0.75

Postoperative thrombotic thrombocytopenic purpura. Surg Today (2013) 0.75

Articles by these authors

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood (2008) 7.06

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59

Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70

Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med (2006) 4.07

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74

Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29

Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02

Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90

von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82

Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med (2003) 2.76

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood (2004) 2.42

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30

Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet (2011) 2.24

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21

Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13

Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 1.94

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood (2002) 1.93

Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87

Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84

The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol (2010) 1.83

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood (2010) 1.76

Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med (2004) 1.69

Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67

Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med (2003) 1.64

Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature (2002) 1.63

Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol (2009) 1.56

Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf (2009) 1.52

Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost (2008) 1.50

Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol (2003) 1.50

Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47

Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist (2007) 1.45

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39

Management of immune thrombocytopenia--something old, something new. N Engl J Med (2010) 1.39

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. Blood (2014) 1.38

Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc (2008) 1.36

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood (2002) 1.29

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27

Syndromes of thrombotic microangiopathy. N Engl J Med (2014) 1.25

Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev (2013) 1.20

Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood (2004) 1.20

Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (2007) 1.19

Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol (2010) 1.18

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer (2013) 1.16

C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14

Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion (2006) 1.14

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13

Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med (2002) 1.11

Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol (2011) 1.10

Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) 1.09

Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol (2010) 1.08

Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol (2008) 1.03

Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med (2014) 1.02

Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol (2007) 1.00

Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost (2005) 0.99

Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis (2002) 0.99

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99

Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion (2004) 0.98

Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res (2002) 0.98

A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes (2007) 0.98

Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol (2008) 0.97

Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 0.95

Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes (2008) 0.95

ADAMTS13 activity in sickle cell disease. Am J Hematol (2006) 0.95

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost (2009) 0.94

An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol (2006) 0.94

Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93

Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol (2011) 0.93

ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol (2003) 0.92

Citrate- vs. acetate-based dialysate in bicarbonate haemodialysis: consequences on haemodynamics, coagulation, acid-base status, and electrolytes. BMC Nephrol (2009) 0.92

D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis (2009) 0.92

Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med (2008) 0.92

Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92